Cette recherche s'applique uniquement aux ressources en bibliothèque.
15 résultats
Trier par:
Ajouter à la liste:
    • Plusieurs versions

    Towards elucidating the radiochemistry of astatine - Behavior in chloroform

    Aneheim, Emma, Palm, Stig, Jensen, Holger, Ekberg, Christian, Albertsson, Per, Lindegren, Sture
    Scientific reports, 04 November 2019, Vol.9(1), pp.15900 [Revue évaluée par les pairs]

    • Plusieurs versions

    Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200

    Lindegren, Sture, Andrade, Luciana N S, Bäck, Tom, Machado, Camila Maria L, Horta, Bruno Brasil, Buchpiguel, Carlos, Moro, Ana Maria, Okamoto, Oswaldo Keith, Jacobsson, Lars, Cederkrantz, Elin, Washiyama, Kohshin, Aneheim, Emma, Palm, Stig, Jensen, Holger, Tuma, Maria Carolina B, Chammas, Roger, Hultborn, Ragnar, Albertsson, Per
    PloS one, 2015, Vol.10(5), pp.e0126298 [Revue évaluée par les pairs]

    • Plusieurs versions

    Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients

    Cederkrantz, Elin, Andersson, Håkan, Bernhardt, Peter, Bäck, Tom, Hultborn, Ragnar, Jacobsson, Lars, Jensen, Holger, Lindegren, Sture, Ljungberg, Michael, Magnander, Tobias, Palm, Stig, Albertsson, Per
    International journal of radiation oncology, biology, physics, 01 November 2015, Vol.93(3), pp.569-576 [Revue évaluée par les pairs]

    • Plusieurs versions

    Synthesis and Evaluation of Astatinated N‑[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates

    Aneheim, Emma, Gustafsson, Anna, Albertsson, Per, Bäck, Tom, Jensen, Holger, Palm, Stig, Svedhem, Sofia, Lindegren, Sture
    Bioconjugate chemistry, 16 March 2016, Vol.27(3), pp.688-697 [Revue évaluée par les pairs]

    • Plusieurs versions

    Alpha particle induced DNA damage and repair in normal cultured thyrocytes of different proliferation status

    Lyckesvärd, Madeleine Nordén, Delle, Ulla, Kahu, Helena, Lindegren, Sture, Jensen, Holger, Bäck, Tom, Swanpalmer, John, Elmroth, Kecke
    Mutation research, July 2014, Vol.765, pp.48-56 [Revue évaluée par les pairs]

    • Plusieurs versions

    Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model

    Gustafsson, Anna M.E, Bäck, Tom, Elgqvist, Jörgen, Jacobsson, Lars, Hultborn, Ragnar, Albertsson, Per, Morgenstern, Alfred, Bruchertseifer, Frank, Jensen, Holger, Lindegren, Sture
    Nuclear medicine and biology, 2012, Vol.39(1), pp.15-22 [Revue évaluée par les pairs]

    • Plusieurs versions

    Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice

    Elgqvist, Jörgen, Andersson, Håkan, Jensen, Holger, Kahu, Helena, Lindegren, Sture, Warnhammar, Elisabet, Hultborn, Ragnar
    Journal of oncology, 2010, Vol.2010, pp.394913 [Revue évaluée par les pairs]

    • Plusieurs versions

    Therapeutic Efficacy of Astatine-211–Labeled Trastuzumab on Radioresistant SKOV-3 Tumors in Nude Mice

    Palm, Stig, Bäck, Tom, Claesson, Ingela, Danielsson, Anna, Elgqvist, Jörgen, Frost, Sofia, Hultborn, Ragnar, Jensen, Holger, Lindegren, Sture, Jacobsson, Lars
    International journal of radiation oncology, biology, physics, 2007, Vol.69(2), pp.572-579 [Revue évaluée par les pairs]

    • Article
    Sélectionner

    Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model

    Andersson, Håkan, Elgqvist, Jörgen, Horvath, György, Hultborn, Ragnar, Jacobsson, Lars, Jensen, Holger, Karlsson, Börje, Lindegren, Sture, Palm, Stig
    Clinical cancer research : an official journal of the American Association for Cancer Research, 01 September 2003, Vol.9(10 Pt 2), pp.3914S-21S [Revue évaluée par les pairs]
    MEDLINE/PubMed (U.S. National Library of Medicine)
    Disponible
    Plus…
    Titre: Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model
    Auteur: Andersson, Håkan; Elgqvist, Jörgen; Horvath, György; Hultborn, Ragnar; Jacobsson, Lars; Jensen, Holger; Karlsson, Börje; Lindegren, Sture; Palm, Stig
    Sujet: Astatine -- Therapeutic Use ; Isotopes -- Therapeutic Use ; Ovarian Neoplasms -- Radiotherapy ; Radioimmunotherapy -- Methods
    Description: The aim of the study was to establish and refine a preclinical model to alpha-immunoradiotherapy of ovarian cancer. At-211 was produced by cyclotron irradiation of a bismuth-209 target and isolated using a novel dry distillation procedure. Monoclonal antibodies were radiohalogenated with the intermediate reagent N-succinimidyl 3-(trimethylstannyl)benzoate and characterized in terms of radiochemical yield and in vitro binding properties. In vitro OVCAR-3 cells were irradiated using an external Cobalt-60 beam, as reference, or At-211-albumin and labeled antibody. Growth assays were used to establish cell survival. A Monte Carlo program was developed to simulate the energy imparted and the track length distribution. Nude mice were used for studies of WBC depression, with various activities of Tc-99m antibodies, as reference, and At-211 antibodies. In efficacy studies, OVCAR-3 cells were inoculated i.p., and animals were treated 2 weeks later. The animals were either dissected 6 weeks later or followed-up for long-term survival. A rapid distillation procedure, as well as a rapid and high-yield, single-pot labeling procedure, was achieved. From growth inhibition data, the relative biological effectiveness of the alpha-emission for OVCAR-3 cells was estimated to be approximately 5, which is in the same range as found in vivo for hematological toxicity. At-211 MOv18 was found to effectively inhibit the development of tumors and ascites, also resulting in long-term survival without significant toxic effect. Use of the short-range, high-linear energy transfer alpha-emitter At-211 conjugated to a surface epitope-recognizing monoclonal antibody appears to be highly efficient without significant toxicity in a mouse peritoneal tumor model, urging a Phase I clinical trial.
    Fait partie de: Clinical cancer research : an official journal of the American Association for Cancer Research, 01 September 2003, Vol.9(10 Pt 2), pp.3914S-21S
    Identifiant: 1078-0432 (ISSN); 14506189 Version (PMID)

    • Plusieurs versions

    Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors

    Bäck, Tom A, Jennbacken, Karin, Hagberg Thulin, Malin, Lindegren, Sture, Jensen, Holger, Olafsen, Tove, Yazaki, Paul J, Palm, Stig, Albertsson, Per, Damber, Jan-Erik, Wu, Anna M, Welén, Karin
    EJNMMI research, 11 February 2020, Vol.10(1), pp.10 [Revue évaluée par les pairs]